AMG 145 added to statin therapy versus placebo and ezetimibe in primary hypercholesterolemia or mixed dyslipidemia

Phase 3, randomised, double-blind trial of evolocumab in hypercholesterolemia and combined dyslipidaemia (5 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in low-density lipoprotein cholesterol at week 12 versus placebo. Started Mar 2013; status: active, not recruiting.